Abstract
Cytokines of the transforming growth factor β (TGF-β) superfamily exert effects on proliferation, apoptosis and differentiation in various cell types. Cancer cells frequently acquire resistance to the anti-proliferative signals of TGF-β, which can be due to mutations in proteins of the signalling cascade. We compared the TGF-β-related signalling properties in B-cell lymphoma cell lines that were sensitive or resistant to TGF-β-induced anti-proliferative effects. TGF-β sensitive cell lines expressed higher cell surface levels of the activin receptor-like kinase 5 (Alk-5), a TGF-β receptor type 1. The expression levels of the other TGF-β and bone morphogenetic protein receptors were comparable in the different cell lines. TGF-β-induced phosphorylation of Smad2 was similar in TGF-β sensitive and resistant cell lines. In contrast, activation of Smad1/5 was restricted to cells that were sensitive to growth inhibition by TGF-β. Moreover, with activin A we detected limited anti-proliferative effects, strong phosphorylation of Smad2, but no Smad1/5 phosphorylation. Up-regulation of the TGF-β target genes Id1 and Pai-1 was identified in the TGF-β sensitive cell lines. Constitutive phosphorylation of MAPK p38 was restricted to the TGF-β sensitive cell lines. Inhibition of p38 MAPK led to reduced sensitivity to TGF-β. We suggest that phosphorylation of Smad1/5 is important for the anti-proliferative effects of TGF-β in B-cell lymphoma. Alk-5 was highly expressed in the sensitive cell lines, and might be important for signalling through Smad1/5. Our results indicate a role for p38 MAPK in the regulation of TGF-β-induced anti-proliferative effects.
MeSH Terms
B-Lymphocytes/drug effects,immunology,metabolism,pathology
Bone Morphogenetic Protein Receptors/metabolism
Cell Line, Tumor
Cell Proliferation/drug effects
Enzyme Activation/drug effects
Growth Inhibitors/pharmacology
Humans
Lymphoma, B-Cell/drug therapy,immunology,pathology
Phosphorylation
Protein Serine-Threonine Kinases/genetics,metabolism
Receptor, Transforming Growth Factor-beta Type I
Receptors, Transforming Growth Factor beta/genetics,metabolism
Signal Transduction/drug effects,immunology
Smad1 Protein/immunology,metabolism
Smad5 Protein/immunology,metabolism
Transforming Growth Factor beta/pharmacology
p38 Mitogen-Activated Protein Kinases/metabolism
Chemicals
Growth Inhibitors
Receptors, Transforming Growth Factor beta
Smad1 Protein
Smad5 Protein
Transforming Growth Factor beta
Protein Serine-Threonine Kinases
p38 Mitogen-Activated Protein Kinases
Bone Morphogenetic Protein Receptors
Receptor, Transforming Growth Factor-beta Type I
TGFBR1 protein, human
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Bakkebø Maren
Department of Immunology, Institute for Cancer Research, Oslo University Hospital Montebello, Oslo, Norway.
Huse Kanutte
Hilden Vera I
Smeland Erlend B
Oksvold Morten P
References (29)
29 references, click to expand
-
A new method for detachment of Dynabeads from positively selected B lymphocytes.
J Immunol Methods. 1992 Feb 5;146(2):195-202
PMID: 1371532
-
TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1.
J Biol Chem. 2009 Jan 16;284(3):1435-42
PMID: 19022773
-
Transforming growth factor beta type I receptor kinase mutant associated with metastatic breast cancer.
Cancer Res. 1998 Nov 1;58(21):4805-10
PMID: 9809982
-
Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors.
J Biol Chem. 2009 Apr 10;284(15):9755-63
PMID: 19224917
-
TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation.
Leukemia. 2004 Dec;18(12):2015-25
PMID: 15470494
-
Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter.
J Biol Chem. 2002 Feb 15;277(7):4883-91
PMID: 11729207
-
p38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in human Burkitt lymphoma B cells BL41.
Mol Biol Cell. 2001 Oct;12(10):3139-51
PMID: 11598198
-
Type I receptor serine-threonine kinase preferentially expressed in pulmonary blood vessels.
Am J Physiol. 1996 Apr;270(4 Pt 1):L547-58
PMID: 8928814
-
The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta.
J Biol Chem. 1999 Dec 10;274(50):35381-7
PMID: 10585406
-
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
EMBO J. 1997 Sep 1;16(17):5353-62
PMID: 9311995
-
Role of transforming growth factor-beta in hematologic malignancies.
Blood. 2006 Jun 15;107(12):4589-96
PMID: 16484590
-
Signaling cross-talk between TGF-beta/BMP and other pathways.
Cell Res. 2009 Jan;19(1):71-88
PMID: 19002158
-
A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras.
Genes Dev. 1999 Apr 1;13(7):804-16
PMID: 10197981
-
Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling.
Circ Res. 2003 Oct 3;93(7):682-9
PMID: 12970115
-
Specificity and versatility in tgf-beta signaling through Smads.
Annu Rev Cell Dev Biol. 2005;21:659-93
PMID: 16212511
-
Transforming growth factor-beta-mediated signaling via the p38 MAP kinase pathway activates Smad-dependent transcription through SUMO-1 modification of Smad4.
J Biol Chem. 2003 Dec 19;278(51):50833-42
PMID: 14514699
-
Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity.
J Biol Chem. 2008 Sep 5;283(36):24308-13
PMID: 18614541
-
Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene.
J Biol Chem. 2002 Feb 1;277(5):3176-85
PMID: 11700304
-
Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition.
Curr Opin Cell Biol. 2009 Apr;21(2):166-76
PMID: 19237272
-
The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes.
Microbes Infect. 1999 Dec;1(15):1297-304
PMID: 10611758
-
Transforming growth factor-beta signaling in normal and malignant hematopoiesis.
J Interferon Cytokine Res. 2007 Jul;27(7):543-52
PMID: 17651015
-
The plasminogen activation system in tumor growth, invasion, and metastasis.
Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
PMID: 10949579
-
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.
Cell. 1996 Aug 23;86(4):543-52
PMID: 8752209
-
Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
J Gen Virol. 2000 Jun;81(Pt 6):1567-78
PMID: 10811940
-
TGFbeta in Cancer.
Cell. 2008 Jul 25;134(2):215-30
PMID: 18662538
-
Balancing BMP signaling through integrated inputs into the Smad1 linker.
Mol Cell. 2007 Feb 9;25(3):441-54
PMID: 17289590
-
Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth.
Mol Cell Biol. 2008 Nov;28(22):6889-902
PMID: 18794361
-
A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells.
Mol Cell. 2003 Apr;11(4):915-26
PMID: 12718878
-
Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis.
Exp Biol Med (Maywood). 2006 May;231(5):534-44
PMID: 16636301